CSL Limited has announced it will be a co-investor in the Government's Biomedical Translation Fund (BTF) which has been developed to stimulate investment in commercialising Australian medical science.
The investment will form part of a fund called the Medical Research Commercialisation Fund (MRCF) which will see $115 million of public funds matched by $115 million of private investment.
Medicines Australia welcomed the move as a strong demonstration of CSL's ongoing committment to research in Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Dec 16
